Company Overview
HeartBeam, Inc. operates within the healthcare sector, specifically functioning as a medical technology company dedicated to the development and commercialization of electrocardiogram solutions designed for detecting and monitoring cardiac disease outside of traditional healthcare facilities. The company's core product offering, the HeartBeam System, is a cable-free and ambulatory 12-lead ECG device that facilitates remote patient monitoring capabilities. Currently, the enterprise maintains a market capitalization of $46.84M and employs a workforce of 16 individuals to execute its strategic initiatives. The combination of a relatively modest market cap and a small employee base indicates that HeartBeam is a micro-cap entity with limited scale, suggesting that its operations are constrained to a niche segment of the broader health information services industry where it seeks to establish a foothold through specialized technology deployment.
Financial Health
The company reports trailing twelve-month revenue of N/A, while reporting a significant net income of $-21,015,000 and an EBITDA of $-21,099,000, highlighting a substantial gap between top-line activity and profitability that reveals a heavy cost structure or significant investment in operational expenses relative to generated sales. Free cash flow stands at $-6,918,982, which indicates that the company is currently burning cash rather than generating liquidity, thereby limiting its financial flexibility for organic growth or capital expenditures without external financing. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that suggests the company is either in a pre-revenue stage or operating at a level where costs completely absorb any revenue generated, resulting in no measurable profitability on a percentage basis. The balance sheet shows cash holdings of $4.38M against debt levels marked as N/A, meaning there are no reported interest-bearing liabilities, which presents a conservative stance despite the lack of traditional leverage metrics. The current ratio is 1.45, indicating that the company possesses 1.45 dollars in current assets for every dollar of current liabilities, which suggests a reasonable level of short-term liquidity to meet its immediate obligations. Return on Equity is -987.3% and Return on Assets is -289.8%, metrics that reveal severe inefficiency or dilution, showing that management has not yet generated positive returns on the capital invested in the business or the assets utilized to generate revenue.
Valuation Assessment
The valuation metrics present a complex picture with a P/E Ratio (TTM) of N/A and a Forward P/E of -2.15, where the negative forward multiple implies that the market expects earnings to remain negative or for the company to continue operating at a loss in the near future. The Price to Book ratio stands at 17.54, indicating that the market is valuing the company at a significant premium of 17.54 times its net asset value, which often suggests high expectations for future growth or a specific intangible asset value not fully captured on the balance sheet. Since Price to Sales is N/A and EV/EBITDA is -2.01, these alternative valuation metrics further underscore the difficulty in applying traditional multiple-based valuation models to a firm with negative earnings and no sales data. The stock's trading range over the past year spans a 52-Week High of $4.00 and a 52-Week Low of $0.54, placing the current price in a wide band of volatility that reflects the high-risk nature of investing in early-stage biotech or medtech firms. The Beta value is -0.80, a negative figure that implies the stock's price moves inversely to the broader market, exhibiting volatility that is distinct from and potentially amplified by market-wide trends in a counter-cyclical manner.
Growth & Income
The company reports Revenue Growth (YoY) of N/A and Earnings Growth (YoY) of N/A, meaning that historical growth rates cannot be calculated to determine if earnings are growing faster or slower than revenue due to the absence of comparable period data. As the dividend yield is N/A and the payout ratio is 0.0%, HeartBeam does not distribute dividends to shareholders, which implies that the company retains all available earnings to reinvest into research, development, and commercialization efforts rather than providing income to investors. This non-dividend status is consistent with the company's stage of development, where capital preservation is prioritized over income distribution to fund the commercialization of the HeartBeam System. The overall growth and income profile is characterized by a complete absence of historical growth data and dividend income, positioning the asset purely as a speculative vehicle based on potential future technological adoption rather than current financial performance.